Targeting PRMT1-Mediated FLT3 Methylation Disrupts Maintenance of MLL- rearranged Acute Lymphoblastic Leukemia.

Relapse remains the main cause of MLL-r Acute Lymphoblastic Leukemia (ALL) treatment failure due to persistence of drug-resistant clones after conventional chemo-treatment or targeted therapy. Thus defining mechanisms underlying MLL-r ALL maintenance is critical to develop effective therapy. PRMT1, which deposits an asymmetric dimethylarginine (ADMA) mark on histone/non-histone proteins, is reportedly overexpressed in various cancers. Here, we demonstrate elevated PRMT1 levels in MLL-r ALL cells and show that inhibition of PRMT1 significantly suppresses leukemic cell growth and survival. Mechanistically, we reveal that PRMT1 methylates FLT3 at arginine (R) residues 972 and 973, and its oncogenic function in MLL-r ALL cells is FLT3 methylation-dependent. Both biochemistry and computational analysis demonstrate that R972/973 methylation could facilitate recruitment of adaptor proteins to FLT3 in a phospho-tyrosine (Y) residue 969 dependent or independent manner. Cells expressing R972/973 methylation-deficient FLT3 exhibited more robust apoptosis and growth inhibition than did Y969 phosphorylation-deficient FLT3-transduced cells. We also show that the capacity of the type I PRMT inhibitor MS023 to inhibit leukemia cell viability parallels baseline FLT3 R972/973 methylation levels. Finally, combining FLT3 tyrosine kinase inhibitor-PKC412 with MS023 treatment enhanced elimination of MLL-r ALL cells relative to PKC412 treatment alone in patient-derived mouse xenografts (PDXs). These results indicate that abolishing FLT3 arginine methylation through PRMT1 inhibition represents a promising strategy to target MLL-r ALL cells.

[1]  Juan Du,et al.  PRMT1-mediated FLT3 arginine methylation promotes maintenance of FLT3-ITD+ Acute Myeloid Leukemia. , 2019, Blood.

[2]  F. Pichiorri,et al.  SIRT1 Activation Disrupts Maintenance of Myelodysplastic Syndrome Stem and Progenitor Cells by Restoring TET2 Function. , 2018, Cell stem cell.

[3]  B. Gjertsen,et al.  GRP94 rewires and buffers the FLT3-ITD signaling network and promotes survival of acute myeloid leukemic stem cells. , 2018, Haematologica.

[4]  S. Richard,et al.  Arginine methylation catalyzed by PRMT1 is required for B cell activation and differentiation , 2017, Nature Communications.

[5]  Amanda C. Winters,et al.  MLL-Rearranged Leukemias—An Update on Science and Clinical Approaches , 2017, Front. Pediatr..

[6]  P. Houghton,et al.  A review of new agents evaluated against pediatric acute lymphoblastic leukemia by the Pediatric Preclinical Testing Program , 2016, Leukemia.

[7]  S. Nimer,et al.  Arginine methyltransferases in normal and malignant hematopoiesis. , 2016, Experimental hematology.

[8]  Kyle V. Butler,et al.  A Potent, Selective, and Cell-Active Inhibitor of Human Type I Protein Arginine Methyltransferases. , 2016, ACS chemical biology.

[9]  L. Silverman,et al.  A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study , 2016, Clinical Cancer Research.

[10]  K. Pietras,et al.  Expression of GADS enhances FLT3-induced mitogenic signaling , 2016, Oncotarget.

[11]  Jun Lu,et al.  The dual function of PRMT1 in modulating epithelial-mesenchymal transition and cellular senescence in breast cancer cells through regulation of ZEB1 , 2016, Scientific Reports.

[12]  Boris Lenhard,et al.  Targeting Aberrant Epigenetic Networks Mediated by PRMT1 and KDM4C in Acute Myeloid Leukemia , 2016, Cancer cell.

[13]  J. Grandis,et al.  PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response. , 2015, The Journal of clinical investigation.

[14]  C. Leslie,et al.  Cross-talk between PRMT1-mediated methylation and ubiquitylation on RBM15 controls RNA splicing , 2015, eLife.

[15]  P. Houghton,et al.  AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia. , 2015, Blood.

[16]  M. Konopleva,et al.  New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia , 2015, Cancer.

[17]  Melissa R. Pergande,et al.  PRMT1 Is a Novel Regulator of Epithelial-Mesenchymal-Transition in Non-small Cell Lung Cancer* , 2015, The Journal of Biological Chemistry.

[18]  D. Beck,et al.  Opposing regulation of BIM and BCL2 controls glucocorticoid-induced apoptosis of pediatric acute lymphoblastic leukemia cells. , 2015, Blood.

[19]  P. Brown,et al.  The Biology and Targeting of FLT3 in Pediatric Leukemia , 2014, Front. Oncol..

[20]  R. Lock,et al.  Stability of gene expression and epigenetic profiles highlights the utility of patient-derived paediatric acute lymphoblastic leukaemia xenografts for investigating molecular mechanisms of drug resistance , 2014, BMC Genomics.

[21]  M. Tallman,et al.  The clinical characteristics, therapy and outcome of 85 adults with acute lymphoblastic leukemia and t(4;11)(q21;q23)/MLL-AFF1 prospectively treated in the UKALLXII/ECOG2993 trial , 2013, Haematologica.

[22]  L. Rönnstrand,et al.  FLT3 signals via the adapter protein Grb10 and overexpression of Grb10 leads to aberrant cell proliferation in acute myeloid leukemia , 2013, Molecular oncology.

[23]  W. Choi,et al.  The MLL recombinome of acute leukemias in 2013 , 2013, Leukemia.

[24]  O. Elemento,et al.  Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia. , 2012, Cancer discovery.

[25]  M. Levis,et al.  Fluvastatin inhibits FLT3 glycosylation in human and murine cells and prolongs survival of mice with FLT3/ITD leukemia. , 2012, Blood.

[26]  Bengt Phung,et al.  Suppressor of Cytokine Signaling 6 (SOCS6) Negatively Regulates Flt3 Signal Transduction through Direct Binding to Phosphorylated Tyrosines 591 and 919 of Flt3* , 2012, The Journal of Biological Chemistry.

[27]  W. Sippl,et al.  Acyl derivatives of p-aminosulfonamides and dapsone as new inhibitors of the arginine methyltransferase hPRMT1. , 2011, Bioorganic & medicinal chemistry.

[28]  S. Liang,et al.  TDRD3 is an effector molecule for arginine-methylated histone marks. , 2010, Molecular cell.

[29]  E. Thiel,et al.  High BAALC expression predicts chemoresistance in adult B-precursor acute lymphoblastic leukemia. , 2010, Blood.

[30]  Kristina Masson,et al.  A role of Gab2 association in Flt3 ITD mediated Stat5 phosphorylation and cell survival , 2009, British journal of haematology.

[31]  En Li,et al.  A Mouse PRMT1 Null Allele Defines an Essential Role for Arginine Methylation in Genome Maintenance and Cell Proliferation , 2009, Molecular and Cellular Biology.

[32]  S. Clarke,et al.  Protein arginine methylation in mammals: who, what, and why. , 2009, Molecular cell.

[33]  J. Khan,et al.  Molecular Characterization of the Pediatric Preclinical Testing Panel , 2008, Clinical Cancer Research.

[34]  Tanzina Chowdhury,et al.  Insights from clinical studies into the role of the MLL gene in infant and childhood leukemia. , 2008, Blood cells, molecules & diseases.

[35]  M. Eguchi,et al.  Outcome of risk-based therapy for infant acute lymphoblastic leukemia with or without an MLL gene rearrangement, with emphasis on late effects: a final report of two consecutive studies, MLL96 and MLL98, of the Japan Infant Leukemia Study Group , 2007, Leukemia.

[36]  I. Herr,et al.  Combined effects of the two reciprocal t(4;11) fusion proteins MLL·AF4 and AF4·MLL confer resistance to apoptosis, cell cycling capacity and growth transformation , 2007, Oncogene.

[37]  K. Goi,et al.  Resistance of infant leukemia with MLL rearrangement to tumor necrosis factor-related apoptosis-inducing ligand: a possible mechanism for poor sensitivity to antitumor immunity , 2006, Leukemia.

[38]  E. Heiss,et al.  Identification of Y589 and Y599 in the juxtamembrane domain of Flt3 as ligand-induced autophosphorylation sites involved in binding of Src family kinases and the protein tyrosine phosphatase SHP2. , 2006, Blood.

[39]  N. Heerema,et al.  Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group. , 2006, Blood.

[40]  S. Armstrong,et al.  Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia. , 2005, Blood.

[41]  Dario Campana,et al.  FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression. , 2005, Blood.

[42]  R. Lock,et al.  Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies. , 2004, Blood.

[43]  J. Radich,et al.  The role of FLT3 in haematopoietic malignancies , 2003, Nature Reviews Cancer.

[44]  Rob Pieters,et al.  Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. , 2003, Cancer cell.

[45]  H. Broxmeyer,et al.  Flt3 ligand induces tyrosine phosphorylation of gab1 and gab2 and their association with shp-2, grb2, and PI3 kinase. , 2000, Biochemical and biophysical research communications.

[46]  H R Herschman,et al.  PRMT1 Is the Predominant Type I Protein Arginine Methyltransferase in Mammalian Cells* , 2000, The Journal of Biological Chemistry.

[47]  D. Birnbaum,et al.  SHC and SHIP phosphorylation and interaction in response to activation of the FLT3 receptor , 1999, Leukemia.

[48]  N. Heerema,et al.  Treatment outcome and prognostic factors for infants with acute lymphoblastic leukemia treated on two consecutive trials of the Children's Cancer Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.